RESUMEN
Immobilization of enzyme could offer the biocatalyst with increased stability and important recoverability, which plays a vital role in the enzyme's industrial applications. In this study, we present a new strategy to build an intelligent enzyme carrier by coating titania nanoparticles with thermoresponsive epoxy-functionalized polymers. Zero-valent copper-mediated living radical polymerization (Cu(0)-LRP) was utilized herein to copolymerize N-isopropylacrylamide (NIPAM) and glycidyl acrylate (GA) directly from an unprotected dopamine-functionalized initiator to obtain an epoxy-containing polymer with terminal anchor for the "grafting to" or "one-pot" modification of titania nanoparticles. A rhodamine B-labeled laccase has been subsequently used as a model enzyme for successful immobilization to yield an intelligent titania/laccase hybrid bifunctional catalyst. The immobilized laccase has shown excellent thermal stability under ambient or even relatively high temperature above the lower critical solution temperature (LCST) at which temperature the hybrid particles could be facilely recovered for reuse. The enzyme activity could be maintained during the repeated use after recovery and enzymatic degradation of bisphenol A was proven to be efficient. The photocatalytic ability of titania was also investigated by fast degradation of rhodamine B under the excitation of simulated sunlight. Therefore, this study has provided a facile strategy for the immobilization of metal oxide catalysts with enzymes, which constructs a novel bifunctional catalyst that will be promising for the "one-pot" degradation of different organic pollutants.
Asunto(s)
Catecoles/química , Enzimas Inmovilizadas/química , Compuestos Epoxi/química , Lacasa/química , Nanopartículas/química , Titanio/química , Acrilamidas/química , Acrilatos/química , Biocatálisis , Cobre/química , Enzimas Inmovilizadas/metabolismo , Lacasa/metabolismo , Rodaminas/químicaRESUMEN
Exosomes, as a class of small extracellular vesicles closely related to the biological behavior of various types of tumors, are currently attracting research attention in cancer diagnosis and treatment. Regarding cancer diagnosis, the stability of their membrane structure and their wide distribution in body fluids render exosomes promising biomarkers. It is expected that exosome-based liquid biopsy will become an important tool for tumor diagnosis in the future. For cancer treatment, exosomes, as the "golden communicators" between cells, can be designed to deliver different drugs, aiming to achieve low-toxicity and low-immunogenicity targeted delivery. Signaling pathways related to exosome contents can also be used for safer and more effective immunotherapy against tumors. Exosomes are derived from a wide range of sources, and exhibit different biological characteristics as well as clinical application advantages in different cancer therapies. In this review, we analyzed the main sources of exosomes that have great potential and broad prospects in cancer diagnosis and therapy. Moreover, we compared their therapeutic advantages, providing new ideas for the clinical application of exosomes.
Asunto(s)
Biomarcadores de Tumor , Exosomas , Neoplasias , Humanos , Exosomas/metabolismo , Exosomas/inmunología , Neoplasias/terapia , Neoplasias/inmunología , Animales , Inmunoterapia/métodos , Biopsia Líquida/métodosRESUMEN
Pancreatic cancer is a highly aggressive malignant tumor, that is becoming increasingly common in recent years. Despite advances in intensive treatment modalities including surgery, radiotherapy, biological therapy, and targeted therapy, the overall survival rate has not significantly improved in patients with pancreatic cancer. This may be attributed to the insidious onset, unknown pathophysiology, and poor prognosis of the disease. It is therefore essential to identify and develop more effective and safer treatments for pancreatic cancer. Tumor immunotherapy is the new and fourth pillar of anti-tumor therapy after surgery, radiotherapy, and chemotherapy. Significant progress has made in the use of immunotherapy for a wide variety of malignant tumors in recent years; a breakthrough has also been made in the treatment of pancreatic cancer. This review describes the advances in immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, oncolytic virus, and matrix-depletion therapies for the treatment of pancreatic cancer. At the same time, some new potential biomarkers and potential immunotherapy combinations for pancreatic cancer are discussed. The molecular mechanisms of various immunotherapies have also been elucidated, and their clinical applications have been highlighted. The current challenges associated with immunotherapy and proposed strategies that hold promise in overcoming these limitations have also been discussed, with the aim of offering new insights into immunotherapy for pancreatic cancer.